🇺🇸 FDA
Patent

US 11859010

Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 11859010 (Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61P, A61P35/00